DC260126 is a novel, and potent small-molecule antagonist of GPR40.

FTBMT is a novel, potent, selective and orally bioavailable GPR52 agonist with antipsychotic and procognitive properties.

ML401 is a novel and potent antagonist of the EBI2 receptor.

DJ-V-159 is a novel and potent agonist for G protein-coupled receptor family C group 6 member A (GPRC6A) with the potential for treating type 2 diabetes mellitus (T2D).

ONC212 (ONC-212; ONC 212), a fluorinated-ONC201 analog, is a novel, potent and selective agonist of GPR132 with anticancer activity.

ML-193 (ML193; CID-1261822; CID1261822) is a novel and potent GPR55 (G protein-coupled receptor 55) antagonist with IC50 of 221 nM.

JNJ-63533054, a glycine benzamide analog, is a potent, selective and brain penetrant agonist of hGPR139 (human G-protein-coupled receptors) with an EC50 of 16 nM.

ML145 (ML-145) is a novel and potent GPR35/CXCR8 antagonist (IC50 = 20.1 nM) with anti-inflammatory activity.

MBX-2982 (SAR-260093) is a novel, potent, selective and orally bioavailable G protein-coupled receptor 119 (GPR119) agonist with the potential for treating type 2 diabetes.

LP-471756 is a novel and potent antagonist of GPR139.